Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

titute
  • Location: Ernest N. Morial Convention Center, Hall E.
  • Additional Abstracts

    In addition to the abstract accepted for presentation, two additional abstracts describing  EphA3 expression and screening in myeloid malignancies were accepted for publication online and in the ASH conference materials. These abstracts outline An Immunohistochemistry (IHC) Screen For EphA3 Positive Tumors and Analysis of EphA3 Expression in Hematologic Malignancies by Quantitative PCR.

    "These published abstracts further detail our ongoing research efforts on EphA3," stated Dr. Geoffrey Yarranton, Chief Scientific Officer and Executive Vice President of Research and Development at KaloBios. "We continue to work to understand EphA3 expression on various tumor types, and we now have a validated EphA3 screening test operative at a CLIA laboratory to screen patients' tumor biopsies before entry into the Phase 2 portion of Study KB004-01 in AML and MDS."

    About KaloBios

    KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

    Currently, KaloBios has three drug development programs:

    • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a Phase 2 study in the United States, Europe and Australia.
    • KB001-A, an anti-PcrV mAb fragment that is partnered exclusively with Sanofi Pasteur and is being developed for the prevention and treatment of Pa infections. KaloBios has retained right
      '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology news :

    1. Cell therapy using patients own bone marrow may present option for heart disease
    2. Report presents designs for study of cancer risks near US nuclear facilities
    3. Entomology 2012 to present 105 insect symposia in November
    4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
    5. The Brain Prize 2012 is presented May 9th
    6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
    7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
    8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
    9. Coral reef experts to present latest coral reef science during July symposium
    10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
    11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/21/2014)... dioxide emissions, the main contributor to global warming, are set ... of 40 billion tonnes. , The 2.5 per cent projected ... Carbon Project, which is co-led in the UK by researchers ... University of East Anglia and the College of Engineering, Mathematics ... comes ahead of the New York Climate Summit, where world ...
    (Date:9/21/2014)... In recent years, new strains of bacteria have emerged ... these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, ... at least 23,000. Despite the urgent need for new ... antibiotics in the past decade. , MIT engineers have ... Using a gene-editing system that can disable any target ...
    (Date:9/21/2014)... MA -- Shellfish such as mussels and barnacles secrete ... or ship hulls, even underwater. Inspired by these natural ... materials that could be used to repair ships or ... their new waterproof adhesives, the MIT researchers engineered bacteria ... mussel proteins as well as a bacterial protein found ...
    Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
    ... Men with type 1 diabetes may be able ... tissue, say Georgetown University Medical Center (GUMC) researchers who ... Cell Biology 50th annual meeting in Philadelphia. Their laboratory ... human spermatogonial stem cells (SSCs) extracted from testicular tissue ...
    ... ANTONIO Do not delay treatment of breast cancer just ... Dr. med, of the German Breast Group. This suggestion ... treatment options on the infant. Loibl presented this data at ... Dec. 8-12, 2010. "At the time we started the ...
    ... the trail of some of the most economically damaging organisms ... water fungus that causes powdery mildew and the water molds ... mildew in cruciferous vegetables and other crops. , "We have ... Professor Sophien Kamoun, head of the Sainsbury Laboratory on the ...
    Cached Biology News:'Grow your own transplant' may be possible for men with type 1 diabetes 2Unique needs and outcomes of pregnant women with breast cancer identified 2Gene hunters tackle crop diseases 2
    (Date:9/20/2014)... (PRWEB) September 20, 2014 ... urological and interventional radiology products and services, has ... subsidiary with Clinicon Corporation for its ... HealthTronics’ portfolio of minimally invasive, mobile, surgical technology—offering ... , Under the agreement, HealthTronics will make available ...
    (Date:9/19/2014)... Sept. 19, 2014  InterMune, Inc. (Nasdaq: ... Memorandum of Understanding to settle the litigation in the ... Plan of Merger dated as of August 22, 2014, ... Inc.  As one term of the Memorandum of Understanding, ... forth in the attached exhibit reflecting the amendment to ...
    (Date:9/19/2014)... 18, 2014 Scientists at NYU Langone Medical Center ... efficiency of the process for turning adult cells into ... including vitamin C. Using the new technique in mice, ... from adult skin cells by more than 20-fold compared ... efficient and reliable, and thus should generally accelerate research ...
    (Date:9/19/2014)... September 19, 2014 Follow ... potential to revolutionize the world has attracted diverse ... and small start-ups. The early years of nanotechnology ... largely due to the high risks involved, which ... earmarked for this evolving technology have been growing ...
    Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
    ... from Nicusa Capital urging BioClinica (Nasdaq: BIOC ) shareholders ... Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy: ... the Board BioClinica, Inc. 826 Newtown-Yardley Rd. Newtown, PA  18940 ... As of May 4, 2011, Nicusa owns 854,119 shares, ...
    ... Mass., May 4, 2011 InVivo Therapeutics (OTCBB: ... groundbreaking technologies for the treatment of spinal cord ... School of Medicine,s Miami Project to Cure Paralysis, ... today announced a strategic research collaboration for the ...
    ... , COLLEGE PARK, Md. It took nearly a decade ... their work identifying the anthrax strain used in the 2001 ... members of the high-powered science team have published the first ... of "microbial forensics" and gave bioterrorism investigators a way to ...
    Cached Biology Technology:This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 2This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 3This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 4This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 5InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 2InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 3InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 4Now, the story can be told how scientists helped ID 'Amerithrax' 2Now, the story can be told how scientists helped ID 'Amerithrax' 3
    ... Ambions 96 well Magnetic-Ring Stand is ... 96 well U-bottom microplates. The stand has ... 96 well microtiter plate footprint. The use ... enables fast and easy magnetic separation. With ...
    ... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
    Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
    ... is a versatile and easy-to use enzyme, ... GCpro Taq DNA Polymerase is prepared from ... containing the DNA polymerase I gene from ... processive 5'-3' DNA polymerase activity. Its inherent ...
    Biology Products: